浸潤性乳管がん治療薬の世界市場レポート2025年

浸潤性乳管がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.6％で、125億5,000万米ドルに成長します。この予測期間の成長は、個別化治療戦略への嗜好の高まり、低侵襲手術手技への需要の高まり、バイオシミラーモノクローナル抗体の承認の高まり、抗体薬物複合体の臨床パイプラインの拡大、価値ベースのがん治療モデルへの注目の高まりなどに起因しています。予測期間中に予想される主な動向には、免疫チェックポイント阻害剤の開発、画像診断と治療システムの統合、患者管理へのデジタルヘルスプラットフォームの導入、マイクロRNAモジュレーターの革新、ナノ粒子ベースのドラッグデリバリーシステムの進歩などがあります。

乳がんの罹患率の増加は、今後数年間の浸潤性乳管がん治療薬市場の成長を促進すると予想されます。乳がんは、乳房内の細胞が制御不能に増殖して悪性腫瘍を形成し、近隣の組織に浸潤したり体の他の部位に転移したりする疾患です。乳がん患者の増加は、肥満や運動不足といった生活習慣に関連した要因によるところが大きく、いずれも乳房組織に悪性腫瘍が発生するリスクを高める。浸潤性乳管がん治療薬は、最も一般的なタイプの乳がんに特化した、的を絞った効果的な治療法を提供することで、乳がんの治療に重要な役割を果たしています。これらの治療は、精密医療によって腫瘍の進行と転移を抑制し、患者の転帰とQOLを向上させる。例えば、米国を拠点とする非営利団体American Cancer Society Facts and Figuresによると、乳がんの新規患者数は2023年の30万590人から2024年には31万3,510人に増加します。このように、乳がんの罹患率の上昇が浸潤性乳管がん治療薬市場の成長に寄与しています。

浸潤性乳管がん（IDC）治療薬市場の主要企業は、副作用を最小限に抑えながら標的治療の精度と有効性を高めるため、抗体薬物複合体などの革新的治療法の開発に注力しています。抗体薬物複合体（ADC）は、抗体と細胞毒性薬剤を組み合わせた特殊ながん治療薬で、健康な組織を温存しながらがん細胞に薬剤を直接デリバリーできます。例えば、2024年1月、インドの製薬会社であるアストラゼネカ・ファーマ・インディア社は、日本の製薬会社である第一三共株式会社と提携し、トラスツズマブ・デルクステカンを発売しました。この抗体薬物複合体は、切除不能または転移性のHER2陽性乳がんの成人患者を対象としています。強力なトポイソメラーゼi阻害剤（deruxtecan）をHER2発現がん細胞に作用させ、標的DNAの損傷とそれに続く細胞死を引き起こします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の浸潤性乳管がん治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の浸潤性乳管がん治療薬市場：成長率分析
• 世界の浸潤性乳管がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の浸潤性乳管がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の浸潤性乳管がん治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の浸潤性乳管がん治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• ホルモン療法
• 世界の浸潤性乳管がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン受容体
• ヒト上皮成長因子受容体2（HER2+）
• トリプルネガティブ乳がん
• 世界の浸潤性乳管がん治療薬市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 腫瘍学クリニック
• その他の用途
• 世界の浸潤性乳管がん治療薬市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• チロシンキナーゼ阻害剤
• ポリADPリボースポリメラーゼ（PARP）阻害剤
• プロテアソーム阻害剤
• 世界の浸潤性乳管がん治療薬市場ホルモン療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アロマターゼ阻害剤
• 選択的エストロゲン受容体モジュレーター
• エストロゲン受容体ダウンレギュレーター
• 黄体形成ホルモン放出ホルモン作動薬

第7章 地域別・国別分析

• 世界の浸潤性乳管がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の浸潤性乳管がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 浸潤性乳管がん治療薬市場：競合情勢
• 浸潤性乳管がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• AstraZeneca plc
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim
• Mylan N.V.
• Daiichi Sankyo
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• BeiGene Ltd
• Dr. Reddy's Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 浸潤性乳管がん治療薬市場2029：新たな機会を提供する国
• 浸潤性乳管がん治療薬市場2029：新たな機会を提供するセグメント
• 浸潤性乳管がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Invasive ductal carcinoma (IDC) therapeutics refers to the medical treatments used to manage and treat invasive ductal carcinoma, the most common form of breast cancer that originates in the milk ducts and spreads to the surrounding breast tissue. The primary goal of these treatments is to eliminate cancer cells, prevent further spread or recurrence, and enhance patient survival and quality of life. Treatment options typically include surgery, chemotherapy, and radiation therapy.

The main drug categories in invasive ductal carcinoma therapeutics are targeted therapy and hormone therapy. Targeted therapy involves treatments that specifically focus on cancer cells by identifying certain molecular markers or genetic characteristics of the tumor, minimizing damage to healthy cells. The different types of IDC include hormone receptor-positive, human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer. These therapies are primarily utilized by hospitals, oncology clinics, and other healthcare providers.

The invasive ductal carcinoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides invasive ductal carcinoma therapeutics market statistics, including the invasive ductal carcinoma therapeutics industry's global market size, regional shares, competitors with the invasive ductal carcinoma therapeutics market share, detailed invasive ductal carcinoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the invasive ductal carcinoma therapeutics market. This invasive ductal carcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The invasive ductal carcinoma therapeutics market size has grown strongly in recent years. It will grow from $8.30 billion in 2024 to $9.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to the rising incidence of breast cancer, increased adoption of combination therapies, growing prevalence of obesity and an aging population, expanded use of hormone receptor testing, and enhanced government support for cancer research.

The invasive ductal carcinoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $12.55 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the growing preference for personalized treatment strategies, increasing demand for minimally invasive surgical techniques, rising approvals of biosimilar monoclonal antibodies, expansion of the clinical pipeline for antibody-drug conjugates, and a stronger focus on value-based cancer care models. Key trends anticipated during the forecast period include the development of immune checkpoint inhibitors, integration of imaging and therapeutic systems, incorporation of digital health platforms into patient management, innovation in microRNA modulators, and advancements in nanoparticle-based drug delivery systems.

The increasing incidence of breast cancer is expected to drive the growth of the invasive ductal carcinoma therapeutics market in the coming years. Breast cancer is a condition in which cells within the breast multiply uncontrollably, forming a malignant tumor that can invade nearby tissues or metastasize to other parts of the body. The rise in breast cancer cases is largely attributed to lifestyle-related factors such as obesity and lack of physical activity, both of which elevate the risk of developing malignant tumors in breast tissue. Invasive ductal carcinoma therapeutics play a critical role in treating breast cancer by providing targeted and effective therapies specifically designed for the most common type of breast cancer. These treatments help limit tumor progression and spread through precision medicine, thereby enhancing patient outcomes and quality of life. For example, according to the American Cancer Society Facts and Figures, a U.S.-based nonprofit organization, the number of new breast cancer cases increased from 300,590 in 2023 to 313,510 in 2024. Thus, the rising incidence of breast cancer is contributing to the growth of the invasive ductal carcinoma therapeutics market.

Leading companies in the invasive ductal carcinoma (IDC) therapeutics market are concentrating on the development of innovative treatments, such as antibody-drug conjugates, to enhance the precision and effectiveness of targeted therapies while minimizing side effects. Antibody-drug conjugates (ADCs) are specialized cancer treatments that combine an antibody with a cytotoxic drug, allowing for the direct delivery of the drug to cancer cells while sparing healthy tissues. For example, in January 2024, AstraZeneca Pharma India Limited, an India-based pharmaceutical company, in partnership with Daiichi Sankyo Company, Limited, a Japan-based pharmaceutical firm, introduced trastuzumab deruxtecan. This antibody-drug conjugate is intended for adult patients with unresectable or metastatic HER2-positive breast cancer. It functions by directing a powerful topoisomerase I inhibitor (deruxtecan) to HER2-expressing cancer cells, leading to targeted DNA damage and subsequent cell death.

In December 2024, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to reinforce its position in the oncology sector by broadening its cancer drug portfolio, accelerating the advancement of innovative therapies, and supporting long-term growth in the cancer treatment market. Seagen Inc. is a U.S.-based biotechnology company focused on developing targeted therapies for invasive ductal carcinoma.

Major players in the invasive ductal carcinoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim, Mylan N.V., Daiichi Sankyo, Astellas Pharma Inc., Eisai Co. Ltd., BeiGene Ltd, Dr. Reddy's Laboratories, Cipla Limited, Seagen Inc., Glenmark Pharmaceuticals, and Olema Pharmaceuticals Inc.

North America was the largest region in the invasive ductal carcinoma therapeutics market in 2024. The regions covered in invasive ductal carcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the invasive ductal carcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The invasive ductal carcinoma therapeutics market consists of revenues earned by entities by providing services such as diagnostic imaging, biopsy procedures, hormone therapy, immunotherapy, and post-treatment monitoring and support care. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive ductal carcinoma therapeutics market also includes sales of diagnostic kits, biopsy tools, and medical devices used in surgical and radiation treatments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Invasive Ductal Carcinoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on invasive ductal carcinoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for invasive ductal carcinoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The invasive ductal carcinoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Targeted Therapy; Hormone Therapy
• 2) By Type: Hormone Receptor; Human Epidermal Growth Factor Receptor 2 (HER2+); Triple-Negative Breast
• 3) By End Use: Hospitals; Oncology Clinics; Other End Uses
• Subsegments:
• 1) By Targeted Therapy: Monoclonal Antibodies; Tyrosine Kinase Inhibitors; Poly ADP Ribose Polymerase (PARP) Inhibitors; Proteasome Inhibitors
• 2) By Hormone Therapy: Aromatase Inhibitors; Selective Estrogen Receptor Modulators; Estrogen Receptor Downregulators; Luteinizing Hormone-Releasing Hormone Agonists
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck And Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Invasive Ductal Carcinoma Therapeutics Market Characteristics

3. Invasive Ductal Carcinoma Therapeutics Market Trends And Strategies

4. Invasive Ductal Carcinoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Invasive Ductal Carcinoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Invasive Ductal Carcinoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Invasive Ductal Carcinoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Invasive Ductal Carcinoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Invasive Ductal Carcinoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Invasive Ductal Carcinoma Therapeutics Total Addressable Market (TAM)

6. Invasive Ductal Carcinoma Therapeutics Market Segmentation

• 6.1. Global Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Hormone Therapy
• 6.2. Global Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Receptor
• Human Epidermal Growth Factor Receptor 2 (HER2+)
• Triple-Negative Breast
• 6.3. Global Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Other End Uses
• 6.4. Global Invasive Ductal Carcinoma Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors
• Poly ADP Ribose Polymerase (PARP) Inhibitors
• Proteasome Inhibitors
• 6.5. Global Invasive Ductal Carcinoma Therapeutics Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators
• Estrogen Receptor Downregulators
• Luteinizing Hormone-Releasing Hormone Agonists

7. Invasive Ductal Carcinoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Invasive Ductal Carcinoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Invasive Ductal Carcinoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market

• 8.1. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Invasive Ductal Carcinoma Therapeutics Market

• 9.1. China Invasive Ductal Carcinoma Therapeutics Market Overview
• 9.2. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Invasive Ductal Carcinoma Therapeutics Market

• 10.1. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Invasive Ductal Carcinoma Therapeutics Market

• 11.1. Japan Invasive Ductal Carcinoma Therapeutics Market Overview
• 11.2. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Invasive Ductal Carcinoma Therapeutics Market

• 12.1. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Invasive Ductal Carcinoma Therapeutics Market

• 13.1. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Invasive Ductal Carcinoma Therapeutics Market

• 14.1. South Korea Invasive Ductal Carcinoma Therapeutics Market Overview
• 14.2. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Invasive Ductal Carcinoma Therapeutics Market

• 15.1. Western Europe Invasive Ductal Carcinoma Therapeutics Market Overview
• 15.2. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Invasive Ductal Carcinoma Therapeutics Market

• 16.1. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Invasive Ductal Carcinoma Therapeutics Market

• 17.1. Germany Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Invasive Ductal Carcinoma Therapeutics Market

• 18.1. France Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Invasive Ductal Carcinoma Therapeutics Market

• 19.1. Italy Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Invasive Ductal Carcinoma Therapeutics Market

• 20.1. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market

• 21.1. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market Overview
• 21.2. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Invasive Ductal Carcinoma Therapeutics Market

• 22.1. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Invasive Ductal Carcinoma Therapeutics Market

• 23.1. North America Invasive Ductal Carcinoma Therapeutics Market Overview
• 23.2. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Invasive Ductal Carcinoma Therapeutics Market

• 24.1. USA Invasive Ductal Carcinoma Therapeutics Market Overview
• 24.2. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Invasive Ductal Carcinoma Therapeutics Market

• 25.1. Canada Invasive Ductal Carcinoma Therapeutics Market Overview
• 25.2. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Invasive Ductal Carcinoma Therapeutics Market

• 26.1. South America Invasive Ductal Carcinoma Therapeutics Market Overview
• 26.2. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Invasive Ductal Carcinoma Therapeutics Market

• 27.1. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Invasive Ductal Carcinoma Therapeutics Market

• 28.1. Middle East Invasive Ductal Carcinoma Therapeutics Market Overview
• 28.2. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Invasive Ductal Carcinoma Therapeutics Market

• 29.1. Africa Invasive Ductal Carcinoma Therapeutics Market Overview
• 29.2. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Invasive Ductal Carcinoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Invasive Ductal Carcinoma Therapeutics Market Competitive Landscape
• 30.2. Invasive Ductal Carcinoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Invasive Ductal Carcinoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. AstraZeneca plc
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Boehringer Ingelheim
• 31.10. Mylan N.V.
• 31.11. Daiichi Sankyo
• 31.12. Astellas Pharma Inc.
• 31.13. Eisai Co. Ltd.
• 31.14. BeiGene Ltd
• 31.15. Dr. Reddy's Laboratories

32. Global Invasive Ductal Carcinoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Invasive Ductal Carcinoma Therapeutics Market

34. Recent Developments In The Invasive Ductal Carcinoma Therapeutics Market

35. Invasive Ductal Carcinoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Invasive Ductal Carcinoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Invasive Ductal Carcinoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Invasive Ductal Carcinoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer